BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

CHMP, BRUKINSA

More Like This

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

BeOne Medicines' biologics manufacturing facility and clinical R&D center in Hopewell, NJ.

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024